- Hong Kong
- /
- Medical Equipment
- /
- SEHK:2160
MicroPort CardioFlow Medtech First Half 2024 Earnings: CN¥0.024 loss per share (vs CN¥0.076 loss in 1H 2023)
MicroPort CardioFlow Medtech (HKG:2160) First Half 2024 Results
Key Financial Results
- Revenue: CN¥223.1m (up 27% from 1H 2023).
- Net loss: CN¥56.5m (loss narrowed by 69% from 1H 2023).
- CN¥0.024 loss per share (improved from CN¥0.076 loss in 1H 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
MicroPort CardioFlow Medtech Earnings Insights
Looking ahead, revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Medical Equipment industry in Hong Kong.
Performance of the Hong Kong Medical Equipment industry.
The company's shares are up 1.6% from a week ago.
Balance Sheet Analysis
While earnings are important, another area to consider is the balance sheet. See our latest analysis on MicroPort CardioFlow Medtech's balance sheet health.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SEHK:2160
MicroPort CardioFlow Medtech
A medical device company, engages in the research, development, and commercialization of transcatheter and surgical solutions for structural heart diseases in the People’s Republic of China and internationally.
High growth potential with excellent balance sheet.